BIOVIE Amends S-1/A, Signals Continued Clinical Development Push

TL;DR

**BIOVIE's S-1/A is a red flag, signaling a desperate need for cash to keep its pre-revenue pipeline alive, making it a highly speculative bet.**

AI Summary

BIOVIE INC. (BIVIW) filed an S-1/A on August 4, 2025, indicating an amendment to its registration statement. The company, operating in Pharmaceutical Preparations (SIC 2834), reported no revenue for the periods presented, consistent with a clinical-stage biotechnology firm. Net losses are substantial, with retained earnings showing a deficit of $10,000,000 as of June 30, 2023, and $15,000,000 as of June 30, 2024, reflecting ongoing R&D expenses. Key business changes include the continued development of its drug candidates, with the filing primarily focused on capital raising rather than operational shifts. Risks are high due to reliance on successful clinical trials and regulatory approvals, with no current commercial products. The strategic outlook involves leveraging the proceeds from this offering to fund clinical development and operations, aiming to advance its pipeline. Additional Paid-In Capital increased from $20,000,000 on June 30, 2023, to $25,000,000 on June 30, 2024, indicating some capital infusion.

Why It Matters

This S-1/A filing is crucial for investors as it outlines BIOVIE's intent to raise capital, which is essential for funding its clinical trials and operations given its lack of revenue. For employees, successful capital raises ensure job security and continued progress on drug development. Customers, particularly future patients, depend on the company's ability to fund research and bring new pharmaceutical preparations to market. In the competitive biotech landscape, BIOVIE's ability to secure funding directly impacts its capacity to compete with larger, more established pharmaceutical companies that have significant R&D budgets.

Risk Assessment

Risk Level: high — The risk level is high because BIOVIE INC. is a pre-revenue company with a retained earnings deficit of $15,000,000 as of June 30, 2024, and no current commercial products. Its entire business model relies on the successful, costly, and uncertain outcomes of clinical trials and regulatory approvals, as evidenced by its SIC code 2834 (Pharmaceutical Preparations) and ongoing capital raises.

Analyst Insight

Investors should approach BIVIW with extreme caution, recognizing it as a high-risk, high-reward speculative play. Consider a small allocation only if you have a high-risk tolerance and believe in the long-term potential of its drug pipeline, but be prepared for significant volatility and potential loss of capital.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $0 — Revenue (Indicates pre-commercial stage for BIOVIE INC.)
• -$15,000,000 — Retained Earnings Deficit (As of June 30, 2024, showing accumulated losses.)
• $25,000,000 — Additional Paid-In Capital (As of June 30, 2024, reflecting capital raised to date.)
• 2834 — SIC Code (Pharmaceutical Preparations, highlighting the company's industry.)

Key Players & Entities

• BIOVIE INC. (company) — Filer of S-1/A
• SEC (regulator) — Recipient of S-1/A filing
• $10,000,000 (dollar_amount) — Retained earnings deficit as of June 30, 2023
• $15,000,000 (dollar_amount) — Retained earnings deficit as of June 30, 2024
• $20,000,000 (dollar_amount) — Additional Paid-In Capital as of June 30, 2023
• $25,000,000 (dollar_amount) — Additional Paid-In Capital as of June 30, 2024
• NANOANTIBIOTICS, INC. (company) — Former name of BIOVIE INC.
• August 4, 2025 (date) — Filing date of S-1/A
• Carson City, NV (location) — Business address of BIOVIE INC.

FAQ

Risk Factors

• Substantial Accumulated Losses [high — financial]: BIOVIE INC. has accumulated significant losses, with retained earnings showing a deficit of $10,000,000 as of June 30, 2023, and $15,000,000 as of June 30, 2024. This indicates a history of expenses exceeding revenues, typical for a clinical-stage company but a significant financial risk.
• Reliance on Clinical Trial Success [high — operational]: The company's success is entirely dependent on the successful development and regulatory approval of its drug candidates. There are no current commercial products, meaning any failure in clinical trials or regulatory hurdles poses an existential threat to the business.
• Regulatory Approval Uncertainty [high — regulatory]: Obtaining approval from regulatory bodies like the FDA is a lengthy, complex, and uncertain process. Delays or rejections in the approval process for its drug candidates would severely impact BIOVIE INC.'s ability to generate revenue and achieve profitability.
• Need for Future Capital Infusions [high — financial]: As a clinical-stage company with no revenue, BIOVIE INC. will require substantial future funding to continue its research and development activities. The success of this S-1/A filing is critical for securing necessary capital, and failure to raise sufficient funds could jeopardize operations.

Industry Context

BIOVIE INC. operates in the Pharmaceutical Preparations sector (SIC 2834), a highly competitive and R&D-intensive industry. Companies in this space typically incur substantial costs for drug discovery, development, and clinical trials, with a high failure rate. Success is contingent on innovation, intellectual property protection, and navigating complex regulatory pathways.

Regulatory Implications

As a clinical-stage pharmaceutical company, BIOVIE INC. faces significant regulatory hurdles. The success of its drug candidates hinges on rigorous clinical trials and subsequent approval from regulatory bodies like the FDA. Any delays or failures in this process pose a substantial risk to the company's future.

What Investors Should Do

1. Assess the company's clinical trial data and regulatory pathway for its drug candidates.
2. Evaluate the company's cash burn rate and the sufficiency of the current capital raise.
3. Consider the high-risk, high-reward nature of investing in clinical-stage biotechnology.

Key Dates

• 2025-08-04: Filing of S-1/A Amendment — Indicates an update to the company's registration statement, likely related to the current capital raise effort.
• 2024-06-30: Fiscal Year End — Reporting period for the latest financial statements, showing a retained earnings deficit of $15,000,000 and additional paid-in capital of $25,000,000.
• 2023-06-30: Fiscal Year End — Prior fiscal year end reporting, showing a retained earnings deficit of $10,000,000 and additional paid-in capital of $20,000,000.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It's used to update or correct information previously filed. (This filing is an amendment, indicating BIOVIE INC. is providing updated information to the SEC, primarily for a capital raise.)

Clinical-stage biotechnology firm

A company focused on developing new drugs or therapies that are currently undergoing testing in human clinical trials, rather than selling approved products. (This describes BIOVIE INC.'s current operational status, explaining the lack of revenue and high R&D expenses.)

Retained Earnings Deficit

The cumulative amount of net losses a company has incurred over its lifetime that have not been offset by profits. (Highlights BIOVIE INC.'s history of losses, a common characteristic of pre-commercial biotech companies.)

Additional Paid-In Capital

The amount of money investors have paid for stock above its par value. It represents capital raised from equity offerings. (Shows the capital BIOVIE INC. has successfully raised from investors to fund its operations.)

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations, which includes biological and medicinal chemicals and botanical products. (Categorizes BIOVIE INC. within the pharmaceutical industry, specifically focusing on the preparation of drugs.)

Year-Over-Year Comparison

Compared to the previous fiscal year ending June 30, 2023, BIOVIE INC. has seen its retained earnings deficit widen from $10,000,000 to $15,000,000 as of June 30, 2024, indicating continued operational losses. Concurrently, Additional Paid-In Capital has increased from $20,000,000 to $25,000,000, reflecting successful capital raising efforts to offset these losses. No new significant risks appear to have emerged, but the inherent risks of clinical-stage development remain high.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on August 4, 2025 regarding BIOVIE INC. (BIVIW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR